An Integrated Substance Abuse-Domestic Violence (SADV) Treatment Outcome Study

An Integrated Substance Abuse-Domestic Violence (SADV) Treatment Outcome Study: A Stage 1 Trial for SADV

Investigators will conduct a randomized trial comparing individual SADV to a manualized comparison condition that focuses on substance use only.

Study Overview

• Status: Completed
• Conditions: Substance Abuse; Domestic Violence
• Intervention / Treatment: Behavioral: Individual Therapy; Behavioral: Individual Drug Counseling manual

Detailed Description

The randomized trial will be informed by previous work developing and refining the interventions and training materials used in the randomized trial.

The focus of this registration is the randomized trial.

• Study Type: Interventional
• Enrollment (Actual): 63
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Connecticut
    • New Haven, Connecticut, United States, 06511
      • Yale New Haven Health System

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• referred by the courts or probation for treatment of substance use and domestic violence and who
• meet current DSM-IV criteria for substance dependence (alcohol, cocaine and marijuana, and who have used that substance within the 30 days prior to the screening session)
• report physical violence in an intimate relationship (pushing, slapping, kicking) within 30 days prior to screening
• can read English at a 6th grade level.

Exclusion Criteria:

• Currently in withdrawal from substances and in need of detoxification (such individuals may be re-evaluated following detoxification)
• Have cognitive impairment (a mini mental state score <25)
• Have psychomotor epilepsy (e.g. impulsivity or rage related symptoms secondary to a seizure disorder, as this medical diagnosis is likely to be a confound in the proposed study)
• Have major medical complications such as a head injury/trauma, or HIV dementia that may also be a confound in the study interventions
• Currently receiving either substance abuse or IPV treatment elsewhere
• Have a lifetime history of any psychotic or bipolar disorder
• Currently suicidal or homicidal.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Individual SADV Therapy; Men referred from court and probation for treatment of substance use and domestic violence related problems will receive 12 weeks of individual therapy that focuses on SADV.	Behavioral: Individual Therapy; 12 weeks individual psychotherapy
Experimental: Manualized comparison condition; Men referred from court and probation for treatment of substance use and domestic violence related problems will receive 12 weeks of therapy using the manual provided that focuses on substance use only.	Behavioral: Individual Drug Counseling manual; 12 weeks using the manual provided

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Days of substance use	Days of substance use weekly from each participant endorsed as Y/N, by Self-report using time line follow back method, verified by alcohol concentration and urine toxicology	Weekly up to 12 weeks
Mean Days of physical violence use	Days of physical violence use weekly from each participant endorsed as Y/N, by Self-report using time line follow back method, verified by female collateral informant	Weekly up to 12 weeks

Collaborators and Investigators

• Sponsor: Yale University
• Collaborators: National Institute on Drug Abuse (NIDA)
• Investigators: Principal Investigator: Caroline Easton, PhD, University of Rochester

Study record dates

Study Major Dates

• Study Start (Actual): July 3, 2007
• Primary Completion (Actual): June 30, 2010
• Study Completion (Actual): June 30, 2010

Study Registration Dates

• First Submitted: August 18, 2025
• First Submitted That Met QC Criteria: August 18, 2025
• First Posted (Actual): August 24, 2025

Study Record Updates

• Last Update Posted (Actual): August 24, 2025
• Last Update Submitted That Met QC Criteria: August 18, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders
• Other Study ID Numbers: 10492 (Other Identifier: CTEP); RDA018284A (Other Grant/Funding Number: NIH)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No